Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
about
Smoke, Smoke, Smoke That CigaretteCombined pharmacotherapy and behavioural interventions for smoking cessationAdditional behavioural support as an adjunct to pharmacotherapy for smoking cessationCombined pharmacotherapy and behavioural interventions for smoking cessationAntidepressants for smoking cessationBehavioural interventions as adjuncts to pharmacotherapy for smoking cessationInterventions for preventing weight gain after smoking cessationAntidepressants for smoking cessationApplying of hierarchical clustering to analysis of protein patterns in the human cancer-associated liverPharmacogenetics of nicotine addiction: role of dopamineCurrent Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care.Asthma discordance in twins is linked to epigenetic modifications of T cellsDeciphering cellular states of innate tumor drug responses.Gender Considerations in Addiction: Implications for Treatment.Pharmacogenetics and nicotine addiction treatment.Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.Current and emerging pharmacotherapies for treating tobacco dependence.Overview of the pharmacogenomics of cigarette smoking.KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction.Genetic influences on delay discounting in smokers: examination of a priori candidates and exploration of dopamine-related haplotypesA genome-wide screen for nicotine dependence susceptibility loci.Identification of pharmacogenetic markers in smoking cessation therapy.Genetic variation in the dopamine pathway and smoking cessation.Tobacco addiction and pharmacogenetics of nicotine metabolism.Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases.Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Association between dopamine receptor 2 TaqIA polymorphisms and smoking behavior with an influence of ethnicity: a systematic review and meta-analysis update.A prospective study of the effects of the DRD2/ANKK1 TaqIA polymorphism and impulsivity on smoking initiation.Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells.Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.Prospective association of dopamine-related polymorphisms with smoking cessation in general care.Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.Adherence to pharmacological smoking cessation interventions: A literature review and synthesis of correlates and barriers.Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency.The potential of pharmacogenomics to treat drug addiction.Effects of dopamine D2 receptor gene polymorphisms on smoking cessation: abstinence and withdrawal symptomsCan pharmacogenetics help smokers quit?
P2860
Q22242313-46040FD6-3E45-41CF-ACFA-EC576C26000AQ24186008-5A996D05-50FF-4473-AAAA-0164C4A41D95Q24186545-A035C234-2A1E-421F-B36C-3BB16ED7D212Q24198116-D087D7F8-B519-48F2-9BC1-AA1A83191D0EQ24201167-51C52300-3611-4EE0-934D-2CCEC6AD640CQ24202466-B8ED9650-8B2D-46B4-AFBB-F6C5C0A6C90EQ24203883-0BA12132-6699-4D4B-9B2D-A40EC797D405Q24246426-290A50B4-CADB-451F-B2CF-0E820E62CE63Q28541543-DE2E1EC5-0880-4F08-8648-26E2B4A3274EQ34132214-21167160-6E41-420C-B49F-2F393DC056FBQ34145173-765E6D4C-E53B-4B5D-B17C-FA1D4994AE2FQ34504968-54729817-BACF-4AE9-A940-20B37D360261Q35012940-D1A48D9E-00BF-49FC-A406-20B65B2B616CQ36082618-996E917D-9043-4C6E-BB39-9C53FA880662Q36192658-6F8111D0-D2E2-4F05-AC84-830FD8F5ED12Q36451754-9A8A8EFB-EE05-4EDC-B463-8456120061C5Q36511661-21A3EDD2-49AA-4D44-ADE1-FFD31543C6EDQ36528263-3ED77E25-363E-4C13-9B5D-A372C36E44DBQ36580581-D765A5C1-BC71-4B1A-AD57-9B2A150D4D11Q36708951-60E6344B-78A2-4F77-A513-3032591E4D97Q36821781-902D0636-50E6-4213-BF47-72695A2540D9Q36837410-A1197FDE-A7AE-4D2E-AF90-33BEABE63847Q36927570-15153330-31B8-443F-AB47-5594E3EF618FQ37127185-D9CDDD4F-5B73-4BF7-B096-E3FEB28935B3Q37264547-37AACEAB-AC5B-4A90-BFD4-0DC7D4853209Q37371779-97E3099E-9B14-40F7-AAF3-CE7CBF1E1B59Q37623502-F4641366-47F4-4EE5-971E-6EB85534C356Q37848476-00F8DAF7-512A-49E2-B46B-3E5B0A0C9506Q38044592-E84F67D9-8009-4A3E-BE59-E4CC5A66D6AFQ39519836-B5D936E9-B00D-4334-B405-3C0C392B4275Q41855504-6C3FDA4A-76C0-4793-8F36-16EE26B4AB61Q42936469-A25EF09F-AE91-4037-881F-08E666185F0EQ43115874-4E1C04DB-ABAA-4199-A299-6E5A1361ED34Q46886425-8C15C4F1-20F6-4848-B142-6E604E2B6A49Q47882474-12F228C0-49A9-435C-908E-163C83516FE0Q48015634-6E394A40-E68F-4571-B0FC-7C02C6B8607EQ51980372-D39B224C-5B4A-44A9-AE79-CFFFDFBCA25AQ52295623-433BB788-1E95-4AC6-AAE8-822C136F8EDCQ57380847-FD31B40F-6C99-4E87-BAC2-AF3476730711Q57380880-9949DE7B-47FD-45EA-809D-981E188F8E30
P2860
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@ast
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@en
type
label
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@ast
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@en
prefLabel
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@ast
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@en
P2093
P2860
P356
P1476
Pharmacogenomics of fluorourac ...... cancer: clinical implications.
@en
P2093
Agnès Tran
Elisabeth Rey
Frederike Lentz
Gérard Pons
Jean-Marc Tréluyer
P2860
P2888
P356
10.1038/SJ.TPJ.6500281
P577
2005-01-01T00:00:00Z